Trial · NCT06049966
Atezolizumab in Large Cell Neuroendocrine Carcinoma
NCT06049966, Phase 1, Completed, Oncology Center of Biochemical Education And Research
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Atezolizumab in Large Cell Neuroendocrine Carcinoma. Trials, record NCT06049966. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06049966
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Atezolizumab in Large Cell Neuroendocrine Carcinoma
- NCT number
- NCT06049966
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 22 participants, actual
- Lead sponsor
- Oncology Center of Biochemical Education And Research
- Conditions
- Large Cell Neuroendocrine Carcinoma of the Lung
- Interventions
- Atezolizumab, Carboplatin, Etoposide
- First posted
- 2023-09-22
- Last updated
- 2026-07-08
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival | From treatment initiation through study completion/data cut-off, assessed up to 70 months. | Progression-free survival was defined as the time from treatment initiation to radiographic disease progression according to RECIST v1.1 or death from any cause, whichever occurred first. Patients without documented disease progression or death were censored at the date of last disease assessment or last follow-up. |
| Primary | Overall survival | From treatment initiation through study completion/data cut-off, assessed up to 70 months. | Overall survival was defined as the time from treatment initiation to death from any cause. Patients alive at the time of data cut-off were censored at the date of last confirmed survival follow-up. |
| Secondary | Overall Response Rate | From treatment initiation through study completion/data cut-off, assessed up to 70 months. | Overall response rate was defined as the proportion of patients achieving complete response or partial response according to RECIST v1.1. |
| Secondary | Duration of Response | From treatment initiation through study completion/data cut-off, assessed up to 70 months. | Duration of response was defined as the time from first documented complete or partial response to radiographic disease progression or death from any cause. |
| Other | Safety and tolerability | From treatment initiation through study completion/data cut-off, assessed up to 70 months. | Safety and tolerability were assessed by the occurrence of treatment-related adverse events and immune-related adverse events during treatment and follow-up. |
| Other | Treatment-free interval | From atezolizumab discontinuation through progression, death, or data cut-off, assessed up to 46 months. | Treatment-free interval was defined, among patients who completed the maximum 24-month atezolizumab maintenance duration without progression, as the time from atezolizumab discontinuation to documented disease progression, death, or last follow-up. |
| Other | Exploratory plasma microRNA analysis | Blood samples collected at predefined study time points during treatment and follow-up, assessed up to 70 months. | Exploratory plasma microRNA expression analysis, including miR-375 and miR-21, was performed in available blood samples. Expression levels were assessed relative to non-cancer volunteer control samples and evaluated descriptively/exploratorily in relation to clinical outcomes. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42526918 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06049966
GET https://conductscience.org/api/trials/v1/NCT06049966/registered